• Troglitazone as a PPARγ Agonist: Deep Dive into Tumor & Meta

  2026-05-12

  Explore how Troglitazone, a potent PPARγ agonist, advances research into both metabolic disease and tumor microenvironment modulation. This article uniquely analyzes recent breakthroughs in SPP1-targeted small molecule screens and their implications for assay design.

• FK866 (APO866): Strategic NAMPT Inhibition in Translational

  2026-05-12

  Explore how FK866 (APO866) is reshaping translational oncology by targeting NAD biosynthesis with precision. This article bridges the latest mechanistic evidence with actionable insights for researchers tackling resistant hematologic and solid tumors. Evidence-based guidance, protocol recommendations, and a forward-looking outlook empower your research with APExBIO's gold-standard NAMPT inhibitor.

• Mitochondrial Calcium Signaling Suppresses Ferroptosis via G

  2026-05-11

  This study reveals a direct mechanistic link between mitochondrial calcium uptake through the MCU and the suppression of ferroptotic cell death, mediated by acetylation of GPX4 at lysine 90. Findings offer new insight into ferroptosis regulation and highlight experimental strategies for dissecting cell death mechanisms in disease models.

• Ferrocenyl Novobiocin Derivatives: Antimalarial and Anticanc

  2026-05-11

  This study pioneers the synthesis of ferrocenyl novobiocin derivatives and systematically compares their biological activity with organic analogues against Plasmodium falciparum and breast cancer cell lines. The approach highlights the impact of organometallic modification on enhancing antimalarial and anticancer efficacy, providing a foundation for future drug discovery targeting multidrug resistance.

• UBC9-Mediated PINK1 SUMOylation: Mitophagy and PD Progressio

  2026-05-10

  This study demonstrates that UBC9 enhances mitophagy and reduces oxidative stress in Parkinson’s disease models by promoting SUMOylation of PINK1 at specific lysine residues. These mechanistic insights suggest UBC9 as a potential modulator of neurodegeneration and highlight methodological advances in studying protein-protein interactions within neurodegenerative pathways.

• Tin Mesoporphyrin IX: Strategic Pathways in Translational HO

  2026-05-09

  This thought-leadership article by APExBIO’s scientific marketing head explores how Tin Mesoporphyrin IX (chloride) enables next-generation research into heme oxygenase biology. Bridging mechanistic insights with actionable guidance, it highlights the compound’s translational relevance in metabolic disease and viral infection models, referencing both foundational and cutting-edge studies. Researchers gain clarity on protocol design, competitive context, and the strategic role of HO inhibition in emerging disease paradigms.

• Applied Insights: Minoxidil Sulphate in Vascular and Hair Re

  2026-05-09

  Minoxidil sulphate is a high-purity research compound enabling detailed exploration of potassium channel dynamics in both vascular and hair growth studies. This article delivers protocol-centric guidance, experimental troubleshooting, and translational insights, leveraging recent peer-reviewed evidence and APExBIO’s trusted supply chain.

• Humanized Mice Advance CES Prodrug PK: HD56 In Vivo-In Vitro

  2026-05-08

  This study establishes humanized mice as superior models for predicting the in vivo pharmacokinetics of carboxylate ester prodrugs such as HD56, which targets FK506 binding proteins. The findings provide a validated framework for addressing species differences in prodrug metabolism, informing future translational research and therapeutic development.

• Neuroligin 1 Proteolysis Regulates Social Memory Maintenance

  2026-05-07

  Liu et al. (2025) demonstrate that social interaction-induced proteolytic processing of neuroligin 1 in the ventral hippocampus is critical for sustaining short-term social memory. This mechanistic insight bridges synaptic remodeling with memory maintenance, offering new directions for neuropsychiatric research.

• DMXAA (Vadimezan): Vascular Disrupting Agent for Cancer Rese

  2026-05-07

  DMXAA (Vadimezan) is a vascular disrupting agent and multi-kinase inhibitor with established efficacy in disrupting tumor vasculature and inducing apoptosis in endothelial cells. It selectively inhibits DT-diaphorase and VEGFR2 signaling, making it a valuable tool for cancer biology research. APExBIO provides validated DMXAA (A8233) for reproducible preclinical workflows.

• Pam3CSK4 as a TLR1/2 Agonist: Applied Workflows & Innovation

  2026-05-06

  Pam3CSK4, a synthetic TLR1/2 agonist from APExBIO, empowers researchers to precisely activate innate immune responses and model inflammatory diseases with high reproducibility. This article delivers protocol enhancements, troubleshooting insights, and cross-disciplinary innovation, maximizing the impact of Pam3CSK4 in translational immunology.

• Isradipine (Dynacirc): Precision Modulation of L-Type Calciu

  2026-05-06

  Isradipine (Dynacirc) is a gold-standard dihydropyridine calcium channel blocker, enabling robust and selective inhibition of L-type channels in both cardiovascular and neuroprotective research. This article delivers actionable protocols, troubleshooting tactics, and comparative workflow insights grounded in recent literature, maximizing the reliability and versatility of Isradipine sourced from APExBIO.

• Reserpine (N1867): Technical Use and Protocol Optimization G

  2026-05-05

  Reserpine (N1867) is a high-purity, bioactive compound used for controlled neurotransmitter depletion and related neuropharmacology research. It is not suitable for diagnostic or medical applications and should be implemented in workflows that can accommodate its solubility and stability requirements.

• Dual-Action Kinase Inhibitors Accelerate p38α MAPK Dephospho

  2026-05-05

  This study reveals that certain kinase inhibitors can both block kinase activity and promote dephosphorylation of their targets by stabilizing unique activation loop conformations. These findings provide a mechanistic basis for designing more potent and specific inhibitors, with broad implications for kinase-driven disease research.

• LLY-507: A Potent SMYD2 Inhibitor for Cancer and Fibrosis Re

  2026-05-04

  LLY507, a highly selective SMYD2 inhibitor from APExBIO, empowers researchers to dissect epigenetic mechanisms in cancer and renal fibrosis with precision. This article details evidence-backed workflows, advanced applications, and troubleshooting insights to maximize LLY507’s impact in translational and preclinical studies.

445 records 18/30 page Previous Next First page 上5页 1617181920 下5页 Last page